Accentrix injection is one of the anti Vegf injections available for use. AntiVegf eye injections are used in certain eye conditions, mainly retinal diseases. One can read more about eye injections. There are a few other antivegf drugs available and more can be read about Avastin and Eyelea. There is also another drug which is used in similar conditions called Ozurdex. This is a sustained release steroid injection.
What is Accentrix injection ?
Ranibizumab is the drug present in accentrix Anti vegf injection. It is sold by Novartis under the brand name of Accentrix in India. Intravitreal ranibizumab injection was first approved by the FDA in 2006 for wet age-related macular degeneration. Since then it has been approved for the treatment of macular edema following retinal vein occlusion and diabetic macular edema. Most recently, it was was approved in 2015 for patients with diabetic retinopathy
What is the difference between Accentrix and Lucentis injections ?
Accentrix and Lucentis are both manufactured by Novartis pharmaceuticals. The name of the drug is Ranibizumab. The brand name was known as Lucentis when it was first launched. Currently in India it is known as Accentrix. So, there is no difference between the two injections.
What are the conditions where the Accentrix injection is used ?
How does Accentrix inection work ?
Accentrix is a recombinant, humanized immunoglobulin antibody fragment developed for intraocular use. Ranibizumab binds to the receptor-binding site on VEGF-A, which inhibits the binding of VEGF molecules to their receptors on the surface of endothelial cells. Ranibizumab blocks all isoforms of VEGF-A. It basically prevents the VEGF molecule from having its desired effect. This is how accentrix reduces macular edema.
Macular edema is swelling or collection of fluid in the central part of the retina. The fluid collection occurs due to 2 main reasons :
- Vascular component – Due to release of VEGF by the diseased retina. This effect of VEGF is counteracted by anti VEGF drugs like Accentrix, Avastin, and Eylea.
- Inflammatory component – The diseased retina also releases different inflammatory mediators, which contribute to the swelling. This inflammatory component is treated by giving intravitreal steroids. As mentioned earlier this is where Ozurdex is used
What is the difference between Avastin and Accentrix eye injections ?
Avastin has a drug called Bevacizumab. This was the first antivegf used for treatment of eye conditions. Though it hasn’t been FDA approved, off label use continues for a variety of ophthalmic conditions.
The active part of the molecule is similar in bevacizumab and ranibizumab. However, bevacizumab is the whole anti-VEGF antibody (150 kD), while ranibizumab is an antibody fragment. Bevacizumab has a longer half-life in the systemic circulation while ranibizumab is believed to penetrate the retina better and has higher affinity to VEGF-A than bevacizumab. In other words Aceentrix injection has better retinal penetration than Avastin.
These differences could have an impact on safety and efficacy of these drugs.
- Because Avastin use is off label for the eye, it is available in higher concentrations, from which the individual intravitreal injections need to be prepared. Multiple injections are prepared from the same vial, and this does carry a minimal risk of infection as compared to the other Anti vegfs which are available in single use vials specially for use in the eye.
- The cost of one injection of Avastin is approximately 1/3rd that of Accentrix.
- Even though it isn’t FDA approved, Avastin has almost similar efficacy as Ranibizumab, and continues to be the injection of choice for those who cannot afford the more expensive Anti Vegf injections.
What is the difference between accentrix and eylea eye injections ?
Eylea is an anti vegf drug known as Aflibercept or Vegf Trap eye. It blocks all the isoforms of VEGF, has a greater binding affinity compared to Ranibizumab, and has a longer duration of action.
The improved pharmacokinetics of aflibercept is thought to decrease the frequency of dosing in patients, with similar efficacy as anti-VEGF antibodies.
- Eylea is more expensive than Ranibizumab, the MRP is double. However, because it has a longer duration of action, the frequency of injections is lesser than that with ranibizumab.
- It is generally reserved for those who are not responding to Accentrix, and there is a need to change the anti vegf.
- However, in patients with worse vision at the beginning, Eylea shows better results than Accentrix.
What is the difference between accentrix and Ozurdex ?
- Accentrix is an intreavitreal Anti Vegf injection, which treats macular edema by blocking VEGF.
- Ozurdex is an intravitreal steroid implant, which continues to release steroid (dexamethasone) gradually into the eye over several weeks. This steroid treats the inflammatory component in macular edema.
- While ozurdex is much more expensive than accentrix, the effect of Accentrix lasts for 4-6 weeks while ozurdex lasts for 4-6 months. However, Ozurdex is associated with the risk of causing raised eye pressure and cataracts, which is rare with accentrix. Also, ozurdex does not work in Wet ARMD.
- In patients with diabetic macular edema and retina vein occlusions, the protocol is to start treatment with an anti vegf, and then switch to ozurdex if the anti vegf injections do not have the desired result.
What is the dose of accentrix injection
Does Accentrix injection need to be repeated ?
Actual treatment protocols vary, but may include strict monthly administrations. This would be considered a fixed schedule. Treatment may also be given “as needed”. Here imaging is done every month and based on the findings of the OCT scan your doctor would treat or not treat.
A popular treatment protocol is the treat and extend protocol. Here the first three injections are given monthly. After which the duration between the injections is increased by 2 weeks from the 4 injection onwards.
What are the side effects ?
As with any intraocular injection, there are some risks. The most commonly reported adverse reactions (>10%) included conjunctival hemorrhage, vitreous floaters, vitreous detachment, increased intraocular pressure, and eye pain. These occasionally occur with any intravitreal injection.
Severe complications are rare, and include:
- retinal detachment
It is rare to lose vision as a result of an intravitreal injection. But if you do develop any of these Red Flag signs, then we recommend that you call our clinic immediately.
- Severe, constant pain
- New worsening pain after the first day
- Significant decrease in vision
- Severe, constant floaters
- Curtain or veil in your vision
How is accentric injection or lucentis injection given ?
Because both accentrix or lucentis injections are given in the eye it becomes important to maintain strict asepctic protocols. In other words these eye injections are given in the operation theatre and not in the out patient clinic.
The patient is taken in the OT and gets comfortable in the OT bed. The eye in which the injection is to be given and the surrounding area is cleaned with an antiseptic and the area is covered with sterile plastic drapes.
A wire speculum is used to open the eye and numbing eyedrops are used to numb the eye. Now the eye injection is given and the eye is patched with some antibiotic eye ointment.
What happens after the eye injection ?
The patient is asked to remove the patch after two hours and start antibioitic eye drops 6 times a day for a week. Patient is also asked to not take a head bath for a day after the injection. Usually your doctor will again see the patient after a week or two.
What is the Accentrix injection cost ?
As mentioned earlier this injection is given in the operation theatre and thus there is a cost involved in administering this injection. The Accentric injection rate in india is 21000 and Eye solutions charges Rs 13000 as charges to give the injection. Thus your total accentirx injection price in india would be around Rs 34000 – 35000.
A brief History of Ranibizumab
The effectiveness of ranibizumab was determined by two pivotal trials: the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) and the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR). MARINA and ANCHOR were the first phase 3 trials to show improvement in visual outcomes for all forms of choroidal neovascularization in NVAMD. Based on this evidence, ranibizumab was approved by the FDA on June 30, 2006, for the treatment of NVAMD.